Avadel Pharmaceuticals (AVDL)
NASDAQ: AVDL
· Real-Time Price · USD
15.33
-0.26 (-1.67%)
At close: Sep 25, 2025, 3:59 PM
15.32
-0.07%
After-hours: Sep 25, 2025, 05:19 PM EDT
-1.67% (1D)
| Bid | 15.03 |
| Market Cap | 1.48B |
| Revenue (ttm) | 221.07M |
| Net Income (ttm) | -2.92M |
| EPS (ttm) | -0.02 |
| PE Ratio (ttm) | -766.5 |
| Forward PE | 18.38 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 16.27 |
| Volume | 986,875 |
| Avg. Volume (20D) | 1,316,971 |
| Open | 15.52 |
| Previous Close | 15.59 |
| Day's Range | 15.25 - 15.62 |
| 52-Week Range | 6.38 - 16.66 |
| Beta | 1.58 |
| Ex-Dividend Date | n/a |
About AVDL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AVDL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AVDL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAvadel Pharmaceuticals is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+14.77%
Avadel Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
4 months ago
+9.61%
Avadel Pharmaceuticals shares are trading higher after the company raised its FY25 sales guidance.
1 month ago · seekingalpha.com
Avadel Pharmaceuticals plc (AVDL) Q2 2025 Earnings Call TranscriptAvadel Pharmaceuticals plc (NASDAQ:AVDL ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Gregory J. Divis - CEO & Director Susan Rodriguez - Chief Operating Officer Th...
2 months ago · businesswire.com
ASL Strategic Value Fund Issues Open Letter to Avadel ShareholdersGREENWICH, Conn. & CHESTERFIELD, Mo.--(BUSINESS WIRE)--ASL Strategic Value Fund, LP (together with its affiliates, “ASL Strategic Value Fund” or “we”), a significant shareholder of Avadel Pharmaceutic...
